La glucosa-6-fosfato deshidrogenasa (G6PDH) como blanco molecular contra Trypanosoma cruzi
Abstract
Chagas disease is a systemic and chronic infection caused by the parasite Trypanosoma cruzi, currently considered endemic in America. The current treatment is based on two drugs: Nifurtimox and Benznidazol.
Both of them present high toxicity, producing severe side effects, being a complicated and little accessible treatment, since it is long and expensive. Current drugs have not demonstrated good efficacy in the chronic phase either, and the emergence of resistance to both of them has been reported. For these reasons, it is of great importance to contribute to the development of new drugs to control this “neglected disease.”
In this work, the enzyme glucose-6-phosphate dehydrogenase (G6PDH) was tested as a molecular target of T. cruzi, since it was shown to be a virulence factor for the infective forms. This protein catalyzes the first reaction of the pentose phosphate pathway, generating NADPH, ribose-5-phosphate and glycolysis
intermediates. Therefore, the molecules capable of inhibiting this crucial enzyme constitute potential drugs for the treatment of Chagas disease.
Downloads
References
Andrade DV, Gollob KJ, Dutra WO. Acute Chagas Disease: New Global Challenges for an Old Neglected Disease. PLoS Negl Trop Dis., 2014; 8 (7):3010.
Ortíz C. Validación de la glucosa-6-fosfato deshidrogenasa de Trypanosoma cruzi, como blanco para el diseño racional de fármacos antichagasicos. [Montevideo, Uruguay.]: Universidad de la República; 2017.
Chiribao ML, Libisch G, Parodi-Talice A, Robello C. Early Trypanosoma cruzi infection reprograms human epithelial cells. Biomed Res Int., 2014; 439-501.
Barrios P, Más M, Giachetto G, Basjmadjián Y, Rodríguez M, Viera AL, et al. Enfermedad de Chagas: transmisión vertical. Descripción de casos clínicos. Rev Médica Urug., 2015; 31 (3): 209-213.
Rosa R, Basmadjián Y, González M, González M, Salvatella R. Actualización clínico-epidemiológica y terapéutica de la enfermedad de Chagas en Uruguay. Rev Médica Urug., 2001; 17 (2): 125–32.
Shigihara T, Hashimoto M, Shindo N, Aoki T. Transcriptome profile of Trypanosoma cruzi-infected cells: simultaneous up- and down-regulation of proliferation inhibitors and promoters, Parasitology Research, 2008; 102 (4):
-722.
Kourbeli V, Chontzopoulou E, Moschovou K, Pavlos D, Mavromoustakos T, Papanastasiou LP. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas
Disease and Leishmaniases. Molecules. 2021; 26 (15): 4629.
Murillo-Godinez G, Enfermedad de Chagas (tripanosomiasis americana). Md. interna Méx. 2018; 34 (6): 959-970.
Lannes-Vieira J, de Araújo-Jorge TC, Soeiro Mde N, Gadelha P, CorrêaOliveira R. The centennial of the discovery of Chagas disease: facing the current challenges. PLoS Negl Trop Dis. 2010 Jun 29;4(6):e645.
Ramponi F, Aerts C, Sartor P, Pinazo M, Freilij H, Guzman C, et al. Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare. Gac Sanit. 2022; (37):102275.
Rivera JLH. Síntesis, caracterización y evaluación de nuevos compuestos con actividad biológica frente a enfermedades infecciosas desatendidas. [México]: Universidad autónoma de Chihuahua; 2022.
Apt B W, Heitmann I, Jercic MI, Jofré L, Muñoz P, San Martín A. Tratamiento antiparasitario de la enfermedad de Chagas. Rev Chil Infect. 2008; 25 (5): 384–389.
Núñez-Mujica G. Control y regulación de la glicólisis de Trypanosoma cruzi y Trypanosoma brucei: Un enfoque teórico. [Bogotá, Colombia.]: Universidad de Los Andes; 2009.
Au SW, Gover S, Lam SVM, Adams MJ. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a estructural NADP(+) molecule and provides insights into enzyme deficiency. Struct Fold Des., 2000; 293-303.
Mercaldi GF, Dawson A, Hunter WN, Cordeiro AT. The structure of a Trypanosoma cruzi glucose-6-phosphate dehydrogenase reveals differences from the mammalian enzyme. FEBS Lett, 2016; 590: 2776-2786.
Gupta S, Cordeiro AT, Michels PA. Glucose-6-phosphate dehydrogenase is the target for the trypanocidal action of human steroids. Mol Biochem Parasitol., 2011; 176(2):112-5.
Ortíz C, Moraca F, Laverriere M, Jordan A, Hamilton N, Comini MA. Glucose 6-phosphate dehydrogenase from trypanosomes: Selectivity for steroids and chemical validation in bloodstream Trypanosoma brucei. Molecules. 2021; 26(2):358.
Naciuk FF, Faria JN, Eufrásio AG, Cordeiro AT, Bruder M. Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from Trypanosoma cruzi. ACS Med. Chem. Lett 2020, 11, 1250-1256.
Aguilera E, Perdomo C, Espindola A, Corvo I, Faral-Tello P, Robello C, et al. A Nature-Inspired Design Yields a New Class of Steroids Against Trypanosomatids Molecules. 2019; 24(20):3800.
Ortíz C, Moraca F Medeiros A, Botta M, Hamilton N, Comini M. Modo de unión y selectividad de los esteroides hacia la glucosa-6-fosfato deshidrogenasa del patógeno Trypanosoma cruzi. [Montevideo, Uruguay.]:Instituto Pasteur de Montevideo; 2016.
Marks PA, Banks J. Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids. Proc. Natl. Acad. Sci. USA, 1960; 46, 447–452
Cordeiro AT, Thiemann OH, Michels PAM. Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg. Med. Chem., 2009; 17, 2483–2489.
Copyright (c) 2024 Lucía Cabillón, Yemina Correa, Valeria De Agostini, Belén Dotti, Noelia López, Michel Massa, Agustina Silva, Ileana Corvo, Lía Randall
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License. that allows sharing the work as long as the initial publication in this magazine is indicated.
